Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Insight Molecular Diagnostics Inc.

Get SEC filing alerts via email and in your feed for Insight Molecular Diagnostics Inc.

IMDX

Insight Molecular Diagnostics Inc.

About Insight Molecular Diagnostics Inc.

Oncocyte Corporation develops molecular diagnostic tests for transplant rejection and cancer therapy response. Its core products include blood-based assays for organ damage detection and oncology biomarkers, serving hospitals, transplant centers, and research institutions. The company leverages proprietary technology, strategic partnerships, and intellectual property to enable decentralized testing, aiming to improve patient outcomes, reduce healthcare costs, and foster innovation in personalized medicine.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Insight Molecular Diagnostics Inc.

1
1
Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Reports 99% Revenue Decline in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Reports 116% Revenue Increase to $4.1 Million for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Reports 126% Revenue Growth, $10.9 Million Net Loss for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Reports 398% Revenue Growth but Increased Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Insight Molecular Diagnostics Inc. Oncocyte Corporation Reports 1,115% Revenue Increase to $2.1 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Insight Molecular Diagnostics Inc. Oncocyte Corporation Reports 25% Revenue Increase but Faces $60.7 Million Net Loss in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Insight Molecular Diagnostics Inc. Oncocyte Corporation Reports Significant Financial Challenges in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments